Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jul 30;300(1):73.
doi: 10.1007/s00438-025-02277-z.

DNA methylation biomarkers in diabetic kidney disease: insights and implications

Ziyi Feng  1   2 , Xiaomu Kong  3 , Liang Ma  4
Affiliations
Review

DNA methylation biomarkers in diabetic kidney disease: insights and implications

Ziyi Feng et al. Mol Genet Genomics. .

Abstract

Diabetic kidney disease (DKD) is a significant consequence of diabetes, markedly contributing to the global burden of end-stage renal disease (ESRD). DKD, a substantial public health challenge, is characterized by elevated urinary albumin excretion and/or reduced glomerular filtration rate. As the primary cause of end-stage renal disease (ESRD), comprehending the prevalence of DKD and investigating relevant biomarkers for diagnosis is imperative. The pathogenesis of DKD is intricate, involving both genetic and epigenetic factors. Among these factors, DNA methylation has surfaced as a pivotal element, offering insights into the progression of DKD and potential therapeutic targets. This review endeavors to synthesize current research on DNA methylation biomarkers in DKD, emphasizing advances and potential clinical applications.

Keywords: Biomarker; DNA methylation; Diabetic kidney disease; Epigenetics.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of Interest: The authors declare that they have no conflict of interest in relation to this work. This research was conducted independently, and no financial or personal relationships with organizations or individuals could have influenced the content of this manuscript.

Similar articles

See all similar articles

References

    1. Ahmed SAH, Ansari SA, Mensah-Brown EPK, Emerald BS (2020) The role of DNA methylation in the pathogenesis of type 2 diabetes mellitus. Clin Epigenetics 12(1):104. https://doi.org/10.1186/s13148-020-00896-4 . (published Online First: 2020/07/13) - DOI
    1. Akhouri V, Majumder S, Gaikwad AB (2023) Targeting DNA methylation in diabetic kidney disease: a new perspective. Life Sci 335:122256. https://doi.org/10.1016/j.lfs.2023.122256 . (published Online First: 2023/11/11) - DOI
    1. Alicic RZ, Rooney MT, Tuttle KR (2017) Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol 12(12):2032–2045. https://doi.org/10.2215/cjn.11491116 . (published Online First: 2017/05/20) - DOI
    1. Assenov CFFSPYMABHCTD, Bock C, Halbritter F et al (2016) Quantitative comparison of DNA methylation assays for biomarker development and clinical applications. Nat Biotechnol 34:726–737. https://doi.org/10.1038/nbt.3605 - DOI
    1. Chen G, Chen H, Ren S et al (2019a) Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease. Kidney Int 96(2):409–420. https://doi.org/10.1016/j.kint.2019.02.020 . (published Online First: 2019/05/19) - DOI

MeSH terms

LinkOut - more resources